ezhaler inhalation device, for relief of various symptoms due to airway obstruction in COPD (chronic bronchitis, emphysema). In October 2015, the combination was approved in the U.S. under the name Utibron Neohaler (indacaterol 27.5 mcg/glycopyrrolate 15.6 mcg) as a twice-daily dual bronchodilator for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. The combination is approved in approximately 80 countries and launched in 40 countries. The LAMA glycopyrronium bromide is approved individually as once-daily Seebri Breezhaler in the EU, Seebri (glycopyrronium) inhalation capsules 50 mcg administered through the Breezhaler device in Japan, and twice-daily Seebri Neohaler in the U.S., where the active ingredient is known as glycopyrrolate. It is approved in approximately 90 countries worldwide. The LABA indacaterol is approved individually as once-daily Onbrez Breezhaler in the EU, Onbrez inhalation capsules delivered through the Breezhaler inhalation device in Japan, and Arcapta Neohaler in the U.S. It is approved in 100 countries worldwide. Neuroscience Gilenya (fingolimod) is an oral therapy approved to treat relapsing forms of multiple sclerosis (MS); and a new class of compounds called sphingosine 1-phosphate receptor modulators. In the U.S., Gilenya is indicated for relapsing forms of MS. In the EU, Gilenya is indicated for adult patients with high disease activity despite treatment with at least one disease modifying agent, or rapidly evolving severe relapsing-remitting MS. Gilenya is approved in approximately 80 countries around the world. Gilenya is licensed from Mitsubishi Tanabe Pharma Corporation. Exelon (rivastigmine tartrate) and Exelon Patch (rivastigmine transdermal system) are cholinesterase inhibitors indicated for the treatment of Alzheimer's disease (AD) dementia and Parkinson's disease (PD) dementia. They are the oral and transdermal formulations, respectively, of the cholinesterase inhibitor rivastigmine. Exelon capsules have been approved in approximately 90 countries. In 2006, Exelon was approved for mild to moderate PD dementia in addition to AD in both the U.S. and the EU. Exelon Patch was approved in 2007 in the U.S. and E.U. and has been approved for the treatment of mild-to-moderate AD in approximately 90 countries, including 20 countries where it is also approved for PD dementia. In 2013, the FDA expanded the approved indication for Exelon Patch to also include the treatment of patients with severe AD. The severe indication is approved in 10 countries. Established Medicines Diovan (valsartan), together with Diovan HCT/Co-Diovan (valsartan and hydrochlorothiazide), is an angiotensin II receptor blocker (ARB) and branded anti-hypertensive medications worldwide. Diovan is an agent approved to treat high blood pressure (including children 6 to 18 years), high-risk heart attack survivors, and patients with heart failure. Diovan is available in approximately 120 countries for treating high blood pressure, in 90 countries for heart failure, and in 70 countries for heart attack survivors. Diovan HCT/Co-Diovan is approved in 100 countries worldwide. Exforge (valsartan and amlodipine besylate) is a single-pill combination of the ARB Diovan and the calcium channel blocker amlodipine besylate. It is available in approximately 100 countries. Exforge HCT (valsartan, amlodipine besylate and hydrochlorothiazide) is a single pill combining three prescribed high blood pressure treatments: an ARB, a calcium channel blocker, and a diuretic (hydrochlorothiazide). It is available in 75 countries. Voltaren/Cataflam (diclofenac sodium/potassium/resinate/free acid) is a non-steroidal anti-inflammatory drug for the relief of symptoms in rheumatic diseases, such as rheumatoid arthritis and osteoarthritis, and for various other inflammatory and pain conditions. It is available in approximately 140 countries. This product is marketed by the company’s Pharmaceuticals division in various dosage forms, including tablets, drops, suppositories, ampoules and topical therapy. In addition, in various countries, the company’s
novartis ag-sponsored adr (NVS:New York)
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01www.novartis.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for NVS.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.